DarioHealth Corp. (DRIO)
- Previous Close
1.4500 - Open
1.4500 - Bid 1.4200 x 100
- Ask 1.4800 x 100
- Day's Range
1.4500 - 1.5000 - 52 Week Range
0.6800 - 4.5800 - Volume
29,541 - Avg. Volume
126,611 - Market Cap (intraday)
43.623M - Beta (5Y Monthly) 1.66
- PE Ratio (TTM)
-- - EPS (TTM)
-1.9300 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.67
DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.
www.dariohealth.com276
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: DRIO
Performance Overview: DRIO
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DRIO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DRIO
Valuation Measures
Market Cap
43.62M
Enterprise Value
36.37M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.05
Price/Book (mrq)
0.75
Enterprise Value/Revenue
1.79
Enterprise Value/EBITDA
-0.67
Financial Highlights
Profitability and Income Statement
Profit Margin
-292.00%
Return on Assets (ttm)
-32.51%
Return on Equity (ttm)
-86.04%
Revenue (ttm)
20.35M
Net Income Avi to Common (ttm)
-54.86M
Diluted EPS (ttm)
-1.9300
Balance Sheet and Cash Flow
Total Cash (mrq)
36.8M
Total Debt/Equity (mrq)
50.81%
Levered Free Cash Flow (ttm)
-7.44M